Posts by Lecia V. Sequist, MD, MPH
-
ASCO 2024 Meeting Highlights
Priscilla Brastianos, MD, Lecia Sequist, MD, MPH, and Jessica Lin, MD, share highlights from the ASCO 2024 conference, including encouraging results from a clinical trial for patients with high grade meningiomas, a new treatment for stage III unresectable EGFR lung cancer, and a palliative care trial.
-
New AI Tool Predicts Six-Year Lung Cancer Risk From a Single CT Scan
Lecia V. Sequist, MD, MPH, Florian J. Fintelmann, MD, and colleagues have created and validated Sybil, a convolutional neural network that requires only one low-dose CT scan to predict future lung cancer, regardless of whether visible lung nodules are present and possibly independent of the patient's smoking history.
Biography
Dr. Sequist is originally from Michigan and studied chemistry at Cornell University. She received her MD from Harvard Medical School and trained in internal medicine at the Brigham and Women’s Hospital and in hematology/oncology at the Dana-Farber Cancer Institute, where she also received an MPH from the Harvard School of Public Health. She joined the faculty at the Mass General Cancer Center in 2005 and has an active clinical and translational research career, as well as a busy practice caring for patients with lung cancer. She is currently the Landry Family Professor of Medicine at Harvard Medical School and the Program Director of the Cancer Early Detection and Diagnostics Clinic at Mass General Cancer Center. She has held grants from the NIH, the DOD, and many private foundations. Dr. Sequist’s research focuses on studying targeted therapeutics for lung cancer and bringing new non-invasive tests like circulating tumor cells and circulating tumor DNA to treat and detect lung cancer. In her free time, she likes to spend time with her husband, two sons and her dog, and is a hockey and dance mom.
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
